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ackground: Lupus nephritis (LN) is the most common and serious complication associated with 
SLE and it results in significant morbidity and mortality. It is known by several studies that 
patients of LN have higher levels of anti-dsDNA and anti-C1q compared with SLE patients 
without renal involvement. The current study was designed to determine and compare the level 
of anti-dsDNA and anti-C1q in patients of SLE with and without lupus nephritis in the Pakistani 
population. This current study was also aimed at providing proof that anti-C1q levels are more prominent 
in LN/non-LN SLE as compared to anti-dsDNA. This project may help in the determination of results in 
Pakistan and contribute to the further confirmation of the sensitivity of anti-C1q. 
Method: The patient samples were collected from Sheikh Zayed hospital, Lahore. These patients were 
clinically diagnosed by the Rheumatologists as SLE and LN positive on the basis of ACR and SLEDAI 
scoring criteria. This study was performed and samples were analyzed in the Department of Medical and 
Laboratory Sciences, Imperial College of Business Study, Lahore on the patient’s serum by ELISA 
technique. 
Result: About 38% (12) patients with LN were positive for anti-dsDNA and 31% (9) SLE patients without 
LN were positive whereas about 38.7% (12) were anti-dsDNA negative in LN cases and 58.6% (17) in SLE 
without LN. In case of anti-C1q 100% (31) of these LN patients were positive and 93.1% (27) patients SLE 
without LN showed positive anti C1q results. Only 6.9% (2) patients showed negative results for anti-C1q 
in LN negative patients 
Conclusion: The higher levels of anti-C1q suggest that it may be a better diagnostic marker for LN than 
that of anti-dsDNA and that it can be helpful in the prognosis of SLE patients. 
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Introduction  
Autoimmunity is the failure of an organism in 
recognizing its own constituent parts as self, thus 
leading to an immune response against its own cells and 
tissues [1]. The loss of self-tolerance due to inadequate 
deletion of central and peripheral auto-reactive 
lymphocytes lead to various autoantibody formations is 
the cause of autoimmunity [2, 3]. 
Systemic lupus erythematosus (SLE) is an 
autoimmune disease that affects multiple organs of the 
body. It exhibits low grade inflammation and may lead 
to fatal damage to different organs [4]. The incidence of 
SLE among women is greater than males. The overall 
worldwide prevalence of SLE ranges from 7.4 in males 
to 159.4 in females per 100,000 people respectively [5]. 
The pathogenesis of SLE involves a multitude of cells 
and molecules that participate in apoptosis, innate and 
adaptive immune responses [6]. SLE patients exhibiting 
abnormal renal function are indicative of lupus 
nephritis. The changes in the renal morphology of SLE 
patient’s biopsy show a wide range of vascular, 
glomerular and tubulointerstitial lesions. It is the most 
common cause of death among the SLE patients around 
the world [7]. Renal disease may also be manifested by 
an increased serum creatinine level, or by the presence 
of hematuria, pyuria, or both. The urine protein-to-
creatinine ratio has been found to be a reliable measure 
of proteinuria in LN [8]. 
The early part of the classical pathway of compliment 
system plays an important role in the protection of 
humans against SLE [9]. Studies have suggested that C1q 
plays an important role in the clearance of apoptotic 
cells, processing of immune complexes from tissues and 
host defence against infections [10]. IgG mainly binds to 
the globular portion of C1q whereas anti-C1q antibodies 
bind to the collagenous portion of C1q and this 
collagenous part is considered as the immunogenic part 
of the molecule [11]. Hereditary deficiency of C1q is a 
high risk for the development of SLE, but on contrary, 
SLE itself causes consumption of C1q in the majority of 
patients who are not C1q deficient by birth [12].  
A significant association has been established between 
the low levels of C1q presence of anti-C1q antibodies. 
But unlike C1q other complements such as C3 and C4 
have varying levels in different SLE patients. Most of the 
observations suggest that the levels of C3 and C4 
decrease quite significantly in SLE patients. It can be 
concluded that in SLE, these autoantibodies are 
produced in response to activation of classical pathway 
and against the collagenous part of C1q complement. 
This autoantibody is also found in patients with 
hypocomplementemic urticarial vasculitis, and 
mesangiocapillary glomerulonephritis [13]. Antibodies 
to double-stranded DNA (Anti-dsDNA) are a group 
of anti-nuclear antibodies and their target antigen is 
double stranded DNA. Anti-dsDNA is found in 40-60% 
of SLE patients, they are associated with renal 
involvement but do not correlate well with disease 
activity [14]. One possible mechanism for anti-dsDNA 
and their role in nephritis is the formation of immune 
complexes that arise by indirect binding to DNA or 
nucleosomes that are adhered to glomerular basement 
membrane (GBM) [15, 16]. 
Different studies have presented contrasting results, 
which make the role of these antibodies controversial in 
the onset of LN [18]. Sinico et al demonstrated high 
levels of anti-C1q and anti-dsDNA in LN [19]. Whereas 
Yang et al reported around 39.7% of LN patients had 
both anti-C1q and anti-dsDNA simultaneously whereas 
14.7% patients had none of them [20]. 
A mounting body of evidence suggests that these 
autoantibodies play pivotal role in the pathogenesis of 
SLE and LN, yet their role is defined poorly. Moreover, 
it is hypothesized that increased levels of anti-dsDNA 
and anti-C1q are associated with prognosis of LN. 
Hence, the current study is designed to determine the 
level of these antibodies and establish its possible 
correlation with disease severity in patients of SLE with 
and without LN. 
Methods 
The samples for this study were obtained from Shaikh 
Zayed Hospital Lahore and they were processed in the 
lab of Imperial Business College. It was a Cross-
Sectional Comparative study and convenient sampling 
technique was used. A total of sample size was 60 
patients in two groups. The first group had SLE patients 
and the second group had LN patients, both type of 
patients were clinically diagnosed by the clinician. Both 
groups included diagnosed case of SLE according to 
American College of Rheumatology criteria (ACR 
criteria) and Systemic lupus erythematosus disease 
activity index (SLEDAI) and excluded pregnant and 
other autoimmune disorder patients. 
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Three (3) ml blood was drawn in gel vacutainer (without 
anticoagulant) from each patient and after 
centrifugation serum was separated and stored at -20 Co 
until the tests were performed. The samples were then 
processed and analysed in the lab and levels of anti-C1q 
and anti-dsDNA (positive = ≥30U/ml) A (positive= ≥75 
U/ml) were estimated via ELISA technique) kits for anti-
C1q (Cat.no.E0344Hu, BIOASAY technology) and anti-
dsDNA (Quanta lite 704650, INOVA diagnostics). 
These kits were based on the indirect ELISA method; 
Diluted patient serum was added to wells and incubated. 
All unbound materials were washed away. After that an 
enzyme conjugate was added which bonded to the 
antibody antigen complex. Excess enzyme conjugate 
was washed off and TMB Chromogenic substrate was 
added. The enzyme conjugate catalytic reaction was 
stopped at a specific time. The intensity of the color 
generated was thus proportional to the amount of bound 
target antibody. The results were read by a micro-well 
reader on BIO-RAD microplate reader Model 550. 
Statistical Analysis 
Mean+SD was given for quantitative variables e.g. age. 
Qualitative variables such as sex and age, they were 
expressed as frequencies and percentages. Two 
independent `t` test was applied to compare serum anti-
C1q and anti-dsDNA levels with LN. Mann-Whitney U 
test was applied for comparison between anti-C1q and 
anti-dsDNA. A p-value of < 0.05 was considered as 
statistically significant. The level of significance in this 
study was 5%. 
Results 
The frequency and percentage of males and female 
patients having LN are shown in table 1. The results 
show that 97% (3) males were positive for LN out of total 
4 male patients whereas 90% (28) of females out of 56 
patients who showed positive LN. The remaining 96.6% 
(28) showed LN negative. 
Frequency and P- value of Anti-C1q  
Frequency and percentage of anti-dsDNA and anti –C1q 
in both groups of SLE with and without lupus nephritis 
were seen. Whereas 100%(31) of these LN positive 
patients showed positive result for anti-C1q and 93.1% 
(27) patients without LN showed positive anti -C1q 
results. Only 6.9% (2) patients showed negative results 
for anti c1q in LN negative patients, these results are 
shown in table 1. Table   displays the values of anti-C1q 
antibody in LN. Table shows the median value of 
108.653 (0.11-424) and a p-value of 0.013 for anti–C1q 
which showed significance in LN patients as compared 
to anti-dsDNA. 
Variables LN(n=30) SLE (n=30) P-value 
Age 
(Mean±SD) 
27.95± 9.78 26.24± 7.53 0.458 
Gender 
Male 3 (97%) 1 (3.4%) -- 
Female 28 (90%) 28 (96.6%) -- 
Autoantibody 
Anti-c1q 31(100%) 27 (93%) 0.013* 
Anti-dsDNA 12 (38%) 9 (31%) 0.314 
Total (N=60) 43 (71.6%) 36 (60%) -- 
Table 1: Diagrammatic distribution of anti-c1q and anti-dsDNA with 
SLE and LN 
Table 2: Median, IQR and P-value of Anti C1q and Anti -dsDNA 
antibody in SLE patient with LN 
Frequency and P-value of Anti-dsDNA 
The table 1 showed that 38% (12) patients with LN were 
positive for anti-dsDNA and about 38.7% (12) were 
anti-dsDNA negative, The percentage for SLE patients 
with positive anti-dsDNA were 31% (9) and 58.6% (17) 
of these patients showed negative anti–dsDNA results. 
Table 2 shows median values and p value of anti-dsDNA 
antibody in LN patients .This table shows the median 
value of 39.85 (0.73-2091) and a p value of 0.314 which 
was insignificant for anti-dsDNA levels. 
Table 3 shows the frequency and percentage of 
complement component C3 and C4 levels in LN positive 
patients and LN negative patients. LN positive patients 
with lower of C3 were found to be 25.8% (8) with the 
majority of patients with having 64% (20) having normal 
C3 levels. Similarly patients belonging to LN negative 
group showed that 34% (10) had low levels of C3 and the 
rest of 55% (16) showed normal C3 levels. Patients 
without LN showed 41.4% (12) low results for C4 and 
48.3% (14) showed normal results, whereas patients of 
LN positive patients showed 34.3% (10) patient to have 
low C4 levels and remaining 58% (18) showed normal 
C4 levels. 
Parameter Median IQR 
Anti-C1q   108.653 0.11-424 
Anti-dsDNA 39.85 0.73-2091 
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Table 3: Variables frequency of C3 and C4 with LN and SLE 
Discussion  
This cross sectional study was performed to determine 
the levels of anti-C1q and anti-dsDNA in SLE patients 
with (and/or without) referral to lupus nephritis. The 
targeted aim of this study was to understand the 
relevance of anti-C1q as a better predictive and 
diagnostic marker for SLE/LN patients in comparison to 
anti-dsDNA. Many studies in the past decade showed 
that anti-C1q has a better diagnostic value as compared 
to anti-dsDNA, which has been used as a gold standard 
for SLE diagnosis for several years. This current study 
comes in agreement with numerous studies but 
simultaneously shows disagreement with a few too with 
respect to the percentages of results in SLE patients. This 
may be due to ethnicity, region and gender differences, 
which can be further studied in the future. 
In the current study, there were 56 (93.3%) females 
and 4(6.6%) males. This number is in agreement with 
Leung et al., and Rasheed et al, who have documented 
92.7% females and 7.3% males, and 95.7% and 7% males 
respectively [21, 22]. The number of males was higher in 
group-II patients with LN 3 (75%) as compared to 
group-I, 1(25%) whereas the frequency of females was 
equal in both groups 28 (50%), thus it is evident that 
number of female SLE patients is more than males. This 
may be due to the hormonal differences between males 
and female that makes female more prone to SLE. 
Similarly in a study conducted by Ding et al, it is 
suggested that out of the total number of SLE patients 
enrolled in their study 458 were females and only 58 
were male patients; therefore we suggest that this female 
to male ratio of affected patients is in accordance to this 
present study [23]. 
In the current study it was seen that anti-C1q levels 
showed significant results in both types of SLE patients. 
All LN patients were positive for anti-C1q [with p value 
(0.013)], whereas in patients without Nephritis 93.1% 
showed positive anti-C1q, and 6.9% showed negative 
anti C1q. Picard et al, agrees with these results 
suggesting that anti-C1q levels remain high in patients 
of SLE with and without LN [24]. 
 In case of anti-dsDNA, 31% patients showed positive 
results whereas 58.6% showed negative results. 
Furthermore, 38.7% LN patients showed anti-dsDNA 
positivity {with p value (0.314)} and equal percentage of 
38.7% to show negative anti-dsDNA levels in LN 
patients. Therefore with regards to anti-C1q levels, this 
study is in agreement with Omrana et al., which showed 
that anti-C1q has a 92.7% sensitivity in SLE patients and 
a specificity of 94.12% respectively [25]. Similarly in 
another study conducted by Birmingham et al, he results 
showed that anti-C1q were significantly higher in 
patients with lupus nephritis in the state of flare with 
63% positive results. Hence the study of Birmingham et 
al  is not in agreement with this study as difference in the 
percentage of positivity are far apart [26]. This varying 
difference between the percentages depends on the 
consideration of active flared LN in Birmingham’s study 
and general LN selection in the present study.  
The current study further suggests that the levels of 
anti-C1q are significantly higher compared to anti-
dsDNA in SLE patients having renal discrepancy as well 
as without renal involvement. Therefore this study can 
be backed by Picard et al findings, which suggest a 73% 
to 19% ratio between anti-C1q and anti-dsDNA [24]. 
However with  respect to the levels of anti-dsDNA 
patients with SLE and nephritis, Radanova et al  study in 
2015 does not come in agreement with the this study. 
Radanova’s study claims a 56.6% level of anti-dsDNA in 
LN patients whereas we suggest the levels to be only 
38.8% [27]. This difference between both the studies 
may be due to the reason that Radanova’s study is based 
on three stages of lupus nephritis flare in patients where 
as our study had no such criteria. 
The patients C3 and C4 levels in present study were 
64% and 58% respectively falling in the normal range, 
whereas 25.8% and 34.3% respectively were below 
normal range. So this way our study shows no 
agreement with Li et al which showed that the C3 levels 
were lowered in LN patients whereas C4 remained 
normal. This difference in results between the present 
study and the study by Li et al may be due to difference 
in patient number and the ethnicity differences [28].  
Levels of creatinine and 24 hour urinary proteins are 
indicative of renal insufficiency and thereof we 
determined these levels in patients with SLE. These 
patients at some stage of disease do develop lupus 
nephritis and increase in the levels of creatinine and 
proteins in urine. This is due to inefficient clearing, 
therefore in the current study all the enrolled patients of 
Variable                        C3 C4 
LN 8 (25.8%) 10 (34.3%) 
SLE 10 (34 % ) 12 (41.4%) 
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lupus nephritis showed elevated levels of creatinine and 
24 hour urinary proteins. Hence these high levels of 
creatinine and 24 hour urinary are in agreement with 
Rasheed et al  and Mok et al  who also described that 
these high levels are indicative of lupus nephritis in SLE 
patients [22, 29].  
Therefore based on our findings we conclude that 
anti-C1q levels are higher in SLE patients as well as in 
lupus nephritis patients in comparison with anti-
dsDNA, hence it is suggestive that anti-dsDNA can be 
replaced by anti-C1q  as  a predictive marker for SLE 
with and without lupus nephritis. It is also suggested 
that anti-C1q is a better and more effective tool for the 
control of SLE as treatments can be initiated before the 
disease enters into a phase of flare. The indication of 
anti-C1q in patient’s serum may be suggestive of SLE 
prevalence and may also pin down the disease 
progressing towards lupus nephritis. Even though anti-
dsDNA was found in SLE patient but its lower levels in 
SLE is suggestive that it may be of least importance with 
regard to application as a diagnostic marker. Instead we 
conclude that anti-C1q could be a more reliable and 
accurate diagnostic marker for lupus nephritis. 
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